A Randomized, Placebo-Controlled, Double-blind, Parallel-Group, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered NGP 555 in Healthy Subjects

Trial Profile

A Randomized, Placebo-Controlled, Double-blind, Parallel-Group, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered NGP 555 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs NGP 555 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors NeuroGenetic Pharmaceuticals
  • Most Recent Events

    • 09 Jan 2017 Results published in the NeuroGenetic Pharmaceuticals Media Release
    • 09 Jan 2017 Status changed from recruiting to completed, according to the NeuroGenetic Pharmaceuticals media releas
    • 04 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top